Una buen manejo técnico de la nutrición y alimentación en Avicultura es un factor importante para lograr un buen desempeño productivo de las aves y como consecuencia una máxima rentabilidad. Sin embargo, esto no tendría una respuesta efectiva si no se logra potencializar la salud del ave, por lo que la vacunación con ciencia, tecnología e innovación se convierte en un factor clave. En este sentido mis felicitaciones al Laboratorio FARVET SAC por el gran paso alcanzado hoy a través de adquirir la licencia comercial para el desarrollo y comercialización de vacunas para la salud animal producidos en: EB66® cell line. Este acontecimiento lo convierte en líder de la producción de vacunas AVIARES en CENTRO Y SUD AMERICA.
VIVALIS (FRANCIA) announces a new EB66® cell line commercial license agreement with
Farvet Farmacológicos Veterinarios :
Nantes & Lyon (France) – 20 June 2012 – VIVALIS (NYSE Euronext: VLS) announced today that it has signed a non-exclusive commercial license agreement for up to three products with Farvet Farmacológicos Veterinarios SAC (“FARVET”) for the development and marketing of animal health vaccines produced in the EB66®cell line.
Under this agreement VIVALIS will transfer the EB66® cell line and know-how to FARVET for the commercial development of poultry-based veterinary vaccines. FARVET will have the rights to commercialize one vaccine product with an option to develop two additional products under the same agreement in selected countries in South and Central America. Upfront and milestone payments along with royalties on net-sales to Vivalis apply to all three candidates.
Dr. Manolo Fernandez Díaz, General Manager of FARVET declared, “This is a major step forward in the growth and future of FARVET, with it being the first company in South America to use VIVALIS’ EB66 ® platform. The benefits of the EB66 ® cell technology for veterinary vaccines demonstrate a unique and revolutionary alternative for the effective antigenic manufacturing of vaccines currently produced in SPF eggs. The high efficiency of the EB66 ® cell technology makes it attractive system and we are very pleased to work with VIVALIS and hope to grow with them in the future.”
Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS jointly stated, “Our expansion of the EB66 ® platform into the South American market has been met with initial success. The benefits of our EB66 ® technology, in particular for veterinary products, allows the efficient production of animal health vaccines in a large scale, cell-based manufacturing platform. In situations where manufacturing in traditional systems such as chicken eggs is not optimal or desired, EB66 ® cells offer an economical alternative for the production of these products. We look forward to further developing our relationship with FARVET as they continue to grow in these highly opportunistic markets.”
Financial terms of the agreement were not disclosed